BioCentury
ARTICLE | Clinical News

NGR-hTNF: Interim Phase II data

June 3, 2013 7:00 AM UTC

Interim data from 55 evaluable patients in the open-label, European Phase II Study NGR016 trial showed that weekly IV infusions of 0.8 µg/m 2 NGR-hTNF in combination with doxorubicin (Arm C) met the p...